{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:04:08Z","timestamp":1784714648099,"version":"3.55.0"},"reference-count":217,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hypoxia and the evolving concept of pseudohypoxia are critical in driving tumor angiogenesis, contributing to malignancy progression and therapeutic resistance. Angiogenesis, a common feature of many solid tumors, is promoted by hypoxia-induced overexpression of pro-angiogenic factors (e.g., VEGF, FGF) and genetic mutations (e.g., VHL, SDH) that stabilize hypoxia-inducible factors (HIF) even in normal oxygen conditions, a phenomenon known as pseudohypoxia. Recent experimental studies challenge the view that hypoxia universally enhances vessel growth. In certain models, severe oxygen deprivation impairs angiogenesis. Furthermore, tumor-mediated metabolic reprogramming can drive immune evasion via HIF stabilization in immune cells. These paradoxes, together with persistent therapy resistance and the limited effectiveness of current anti-angiogenic treatments, reveal critical gaps in our understanding of how hypoxic signaling modulates vascular and immune dynamics within the tumor microenvironment. These complexities demand more detailed exploration of underlying processes and the development of innovative therapeutic strategies. Here, we review recent mechanistic studies on tumor angiogenesis, summarizing therapeutic and diagnostic advances from both preclinical and clinical studies. We further discuss strategies to exploit hypoxic vulnerabilities, including HIF inhibitors, hypoxia-activated prodrugs, vascular normalization, combination regimens to restore immunity, biomarker-guided patient selection, and advanced hypoxia-targeted imaging to improve outcomes in angiogenesis-driven cancers.<\/jats:p>","DOI":"10.3390\/cells15141295","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:18:31Z","timestamp":1784553511000},"page":"1295","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-1305","authenticated-orcid":false,"given":"Michael","family":"Boulis","sequence":"first","affiliation":[{"name":"Naresh K. Vashisht College of Medicine, Texas A&M University, Bryan, TX 77807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9570-6403","authenticated-orcid":false,"given":"Fady","family":"Tawfik","sequence":"additional","affiliation":[{"name":"College of Medicine, Howard University, Washington, DC 20059, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-9333","authenticated-orcid":false,"given":"Anitha Kota","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Naresh K. Vashisht College of Medicine, Texas A&M University, Bryan, TX 77807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006493130855","article-title":"Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling","volume":"50","author":"Patan","year":"2000","journal-title":"J. Neurooncol."},{"key":"ref_2","first-page":"1","article-title":"New insights in vascular development: Vasculogenesis and endothelial progenitor cells","volume":"38","author":"Plendl","year":"2009","journal-title":"Anat. Histol. Embryol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shi, Z., Yao, C., Shui, Y., Li, S., and Yan, H. (2023). Research progress on the mechanism of angiogenesis in wound repair and regeneration. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1284981"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1381612824666171227220815","article-title":"The Role of Angiogenesis in Coronary Artery Disease: A Double-Edged Sword: Intraplaque Angiogenesis in Physiopathology and Therapeutic Angiogenesis for Treatment","volume":"24","author":"Wu","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10456-024-09911-1","article-title":"Microglia in retinal angiogenesis and diabetic retinopathy","volume":"27","author":"Hu","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_6","first-page":"603","article-title":"Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies","volume":"50","author":"Zhao","year":"2025","journal-title":"Bioact. Mater."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a041172","DOI":"10.1101\/cshperspect.a041172","article-title":"Targeting angiogenesis via resolution of inflammation","volume":"13","author":"Kelly","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bigos, K.J., Quiles, C.G., Lunj, S., Smith, D.J., Krause, M., Troost, E.G., West, C.M., Hoskin, P., and Choudhury, A. (2024). Tumour response to hypoxia: Understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1331355"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sebesty\u00e9n, A., Kopper, L., Dank\u00f3, T., and T\u00edm\u00e1r, J. (2021). Hypoxia signaling in cancer: From basics to clinical practice. Pathol. Oncol. Res., 27.","DOI":"10.3389\/pore.2021.1609802"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2020.05.015","article-title":"Hypoxia: Turning vessels into vassals of cancer immunotolerance","volume":"487","author":"Schito","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/cas.13990","article-title":"Hypoxia\/pseudohypoxia-mediated activation of hypoxia-inducible factor-1\u03b1 in cancer","volume":"110","author":"Hayashi","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00441-018-2801-6","article-title":"Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma","volume":"372","author":"Kluckova","year":"2018","journal-title":"Cell Tissue Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-06-2510","article-title":"Pseudohypoxic pathways in renal cell carcinoma","volume":"13","author":"Bratslavsky","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Henegan, J.C., and Gomez, C.R. (2016). Heritable cancer syndromes related to the hypoxia pathway. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00068"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ronghe, R., and Tavares, A.A.S. (2024). The skeleton: An overlooked regulator of systemic glucose metabolism in cancer?. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1481241"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"2941","article-title":"Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor","volume":"6","author":"Laderoute","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, X., Bove, A.M., Simone, G., and Ma, B. (2020). Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.599281"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Szymczyk, J., Sluzalska, K.D., Materla, I., Opalinski, L., Otlewski, J., and Zakrzewska, M. (2021). FGF\/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers, 13.","DOI":"10.3390\/cancers13225796"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.3892\/ol.2016.5287","article-title":"Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer","volume":"12","author":"Hung","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-019-0156-9","article-title":"NCAM1\/FGF module serves as a putative pleuropulmonary blastoma therapeutic target","volume":"8","author":"Shukrun","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/sj.bjc.6605788","article-title":"Activation of the EGFR\/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands","volume":"103","author":"Lujan","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pikul, J., Machnicki, M.M., Rzepakowska, A., Winiarska, N., Chudy, A., Moskowicz, A., Kr\u00f3l, K., Fus, \u0141., Kostrzewa, G., and Stok\u0142osa, T. (2025). Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas. BMC Cancer, 25.","DOI":"10.1186\/s12885-024-13421-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: Pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., and Wang, A. (2022). Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1035323"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13619-025-00223-3","article-title":"Dissecting endothelial cell heterogeneity with new tools","volume":"14","author":"Zhong","year":"2025","journal-title":"Cell Regen."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"nwae231","DOI":"10.1093\/nsr\/nwae231","article-title":"Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers","volume":"11","author":"Li","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e009482","DOI":"10.1136\/jitc-2024-009482","article-title":"Low-dose photodynamic therapy promotes vascular E-selectin expression in chest malignancies, improving immune infiltration and tumor control","volume":"13","author":"Chriqui","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Camarillo, C., Ruiz-Garc\u00eda, E., Starling, N., and Marchat, L.A. (2020). Editorial: Neovascularization, angiogenesis and vasculogenic mimicry in cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01140"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.semcdb.2011.10.006","article-title":"Regulation of blood vessel sprouting","volume":"22","author":"Chappell","year":"2011","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Korablev, A.V., Sesorova, I.S., Sesorov, V.V., Vavilov, P.S., Mironov, A., Zaitseva, A.V., Bedyaev, E.V., and Mironov, A.A. (2024). New interpretations for sprouting, intussusception, ansiform, and coalescent types of angiogenesis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168575"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20130686","DOI":"10.1259\/bjr.20130686","article-title":"Vasculogenesis: A crucial player in the resistance of solid tumours to radiotherapy","volume":"87","author":"Brown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107805","DOI":"10.1016\/j.pharmthera.2021.107805","article-title":"Vasculogenic mimicry, a complex and devious process favoring tumorigenesis\u2014Interest in making it a therapeutic target","volume":"223","author":"Treps","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"151321","DOI":"10.1016\/j.ejcb.2023.151321","article-title":"Understanding cancer stem cells and plasticity: Towards better therapeutics","volume":"102","author":"Warrier","year":"2023","journal-title":"Eur. J. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","article-title":"Vessel co-option in cancer","volume":"16","author":"Kuczynski","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Maddison, K., Bowden, N.A., Graves, M.C., and Tooney, P.A. (2023). Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: A systematic review. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10659-y"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/138161212799504902","article-title":"Multiple biological activities of lactic acid in cancer: Influences on tumor growth, angiogenesis and metastasis","volume":"18","author":"Dhup","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3119375","DOI":"10.1155\/2022\/3119375","article-title":"Tumor microenvironment: Lactic acid promotes tumor development","volume":"2022","author":"Gao","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108519","DOI":"10.1016\/j.pharmthera.2023.108519","article-title":"Lactate acidosis and simultaneous recruitment of TGF-\u03b2 leads to alter plasticity of hypoxic cancer cells in tumor microenvironment","volume":"250","author":"Rastogi","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","article-title":"Acidity generated by the tumor microenvironment drives local invasion","volume":"73","author":"Estrella","year":"2013","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"43634","DOI":"10.1074\/jbc.M111.310128","article-title":"WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia","volume":"286","author":"McCarty","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/ncomms6852","article-title":"The Wilms\u2019 tumour suppressor WT1 is a major regulator of tumour angiogenesis and progression","volume":"5","author":"Wagner","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wagner, K.-D., El Ma\u00ef, M., Ladomery, M., Belali, T., Leccia, N., Michiels, J.-F., and Wagner, N. (2019). Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms\u2019 Tumor Suppressor Wt1. Cells, 8.","DOI":"10.3390\/cells8010041"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1038\/s41388-021-01915-1","article-title":"Direct phosphorylation and stabilization of HIF-1\u03b1 by PIM1 kinase drives angiogenesis in solid tumors","volume":"40","author":"Casillas","year":"2021","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"122890","DOI":"10.1016\/j.lfs.2024.122890","article-title":"HIF-1 mediated metabolic reprogramming in cancer: Mechanisms and therapeutic implications","volume":"352","author":"Taneja","year":"2024","journal-title":"Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.12.011","article-title":"Tumor hypoxia: From basic knowledge to therapeutic implications","volume":"88","author":"Liao","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Liu, L., Yu, J., Liu, Y., Xie, L., Hu, F., and Liu, H. (2025). Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1572909"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wei, X., Hou, Y., Long, M., Jiang, L., and Du, Y. (2022). Molecular mechanisms underlying the role of hypoxia-inducible factor-1 \u03b1 in metabolic reprogramming in renal fibrosis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.927329"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-111-1-95_2","article-title":"Alpha-interferon therapy and cutaneous vascular lesions","volume":"111","author":"Dreno","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Emini Veseli, B., Van Wielendaele, P., Delibegovic, M., Martinet, W., and De Meyer, G.R.Y. (2021). The PFKFB3 inhibitor AZ67 inhibits angiogenesis independently of glycolysis inhibition. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115970"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12967-023-04830-z","article-title":"Targeting the SphK1\/S1P\/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"35114","DOI":"10.18632\/oncotarget.26210","article-title":"MicroRNA expression profile during different conditions of hypoxia","volume":"9","author":"Lacedonia","year":"2018","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15878","DOI":"10.1074\/jbc.M800731200","article-title":"MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3","volume":"283","author":"Fasanaro","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13287-020-01881-7","article-title":"HIF-1\u03b1 overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis","volume":"11","author":"Sun","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Monaci, S., Coppola, F., Filippi, I., Falsini, A., Carraro, F., and Naldini, A. (2024). Targeting hypoxia signaling pathways in angiogenesis. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1408750"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Vetsika, E.-K., Koukos, A., and Kotsakis, A. (2019). Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells, 8.","DOI":"10.3390\/cells8121647"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","article-title":"Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation","volume":"39","author":"Li","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2020.09.009","article-title":"Romance of the three kingdoms in hypoxia: HIFs, epigenetic regulators, and chromatin reprogramming","volume":"495","author":"Chen","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Thakur, C., Qiu, Y., Fu, Y., Bi, Z., Zhang, W., Ji, H., and Chen, F. (2022). Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.971288"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e159839","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: Cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.tibs.2025.06.005","article-title":"The HIF axes in cancer: Angiogenesis, metabolism, and immune-modulation","volume":"50","author":"Koh","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R1072","DOI":"10.1152\/ajpregu.00209.2018","article-title":"Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment","volume":"315","author":"Schito","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.yexcr.2017.03.007","article-title":"Hypoxia, pseudohypoxia and cellular differentiation","volume":"356","author":"Mohlin","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","article-title":"Metabolic adaptation in hypoxia and cancer","volume":"502","author":"Paredes","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.beem.2010.10.004","article-title":"Pheochromocytomas: The (pseudo)-hypoxia hypothesis","volume":"24","author":"Favier","year":"2010","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/BJ20040620","article-title":"Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-\u03b1-prolyl-4-hydroxylases","volume":"381","author":"Marxsen","year":"2004","journal-title":"Biochem. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"549412","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies","volume":"2015","author":"Zimna","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.freeradbiomed.2020.12.452","article-title":"Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer","volume":"170","author":"Wu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chest.2016.09.001","article-title":"Hypoxic pulmonary vasoconstriction: From molecular mechanisms to medicine","volume":"151","author":"Wu","year":"2017","journal-title":"Chest"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11033-015-3857-y","article-title":"Introduction to the molecular basis of cancer metabolism and the Warburg effect","volume":"42","author":"Ngo","year":"2015","journal-title":"Mol. Biol. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1038\/sj.onc.1209589","article-title":"Mitochondria in cancer","volume":"25","author":"Kroemer","year":"2006","journal-title":"Oncogene"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2016.07.004","article-title":"Mitochondrial akt regulation of hypoxic tumor reprogramming","volume":"30","author":"Chae","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ruckenstuhl, C., B\u00fcttner, S., Carmona-Gutierrez, D., Eisenberg, T., Kroemer, G., Sigrist, S.J., Fr\u00f6hlich, K.-U., and Madeo, F. (2009). The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004592"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"104844","DOI":"10.1016\/j.critrevonc.2025.104844","article-title":"Novel insight into the Warburg effect: Sweet temptation","volume":"214","author":"Zhang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e162480","DOI":"10.1172\/JCI162480","article-title":"Von Hippel-Lindau disease: Insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc.2018.14","article-title":"Non-angiogenic tumours and their influence on cancer biology","volume":"18","author":"Donnem","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1148\/rg.2018170156","article-title":"Tumors in von Hippel-Lindau Syndrome: From Head to Toe\u2014Comprehensive State-of-the-Art Review","volume":"38","author":"Ganeshan","year":"2018","journal-title":"Radiographics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1\u03b1 in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/hmg\/ddi359","article-title":"Mitochondrial succinate is instrumental for HIF1\u03b1 nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions","volume":"14","author":"Favier","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cen.14289","article-title":"A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma","volume":"93","author":"MacFarlane","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Juhlin, C.C., and Mete, O. (2026). The Role of the Surgical Pathologist in the Recognition of Hereditary SDH-Deficient Tumor Syndromes. Adv. Anat. Pathol., ahead of print.","DOI":"10.1097\/PAP.0000000000000541"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1196\/annals.1353.023","article-title":"Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas","volume":"1073","author":"Dahia","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1210\/jc.2006-0920","article-title":"Expression of HIF-1\u03b1, HIF-2\u03b1 (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations","volume":"91","author":"Pollard","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bakleh, M.Z., and Al Haj Zen, A. (2025). The Distinct Role of HIF-1\u03b1 and HIF-2\u03b1 in Hypoxia and Angiogenesis. Cells, 14.","DOI":"10.3390\/cells14090673"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Tirpe, A.A., Gulei, D., Ciortea, S.M., Crivii, C., and Berindan-Neagoe, I. (2019). Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246140"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J. Physiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/path.6026","article-title":"Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype","volume":"259","author":"Celada","year":"2023","journal-title":"J. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): An open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2022.07.105","article-title":"Hypoxia damages endothelial cell angiogenic function by reducing the Ca2+ restoring ability of the endoplasmic reticulum","volume":"626","author":"Yan","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/bloodadvances.2020002832","article-title":"Hypoxia favors chemoresistance in T-ALL through an HIF1\u03b1-mediated mTORC1 inhibition loop","volume":"5","author":"Fahy","year":"2021","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e202300551","DOI":"10.1002\/cmdc.202300551","article-title":"Hypoxia: Intriguing feature in cancer cell biology","volume":"19","author":"Chowdhury","year":"2024","journal-title":"ChemMedChem"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Magar, A.G., Morya, V.K., Kwak, M.K., Oh, J.U., and Noh, K.C. (2024). A Molecular Perspective on HIF-1\u03b1 and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063313"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"25517","DOI":"10.1073\/pnas.2005467117","article-title":"Alternative proton-binding site and long-distance coupling in Escherichia coli sodium\u2014Proton antiporter NhaA","volume":"117","author":"Henderson","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"73892","DOI":"10.18632\/oncotarget.18029","article-title":"Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.cdd.4400810","article-title":"Hypoxia induces the expression of the pro-apoptotic gene BNIP3","volume":"8","author":"Guo","year":"2001","journal-title":"Cell Death Differ."},{"key":"ref_115","first-page":"2220","article-title":"Angiopoietin-like protein 2 facilitates non-small cell lung cancer progression by promoting the polarization of M2 tumor-associated macrophages","volume":"7","author":"Wei","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10456-024-09957-1","article-title":"Inhibition of Angiopoietin-2 rescues sporadic brain arteriovenous malformations by reducing pericyte loss","volume":"28","author":"Tu","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_117","first-page":"7163","article-title":"Fibroblast growth factors are required for efficient tumor angiogenesis","volume":"60","author":"Compagni","year":"2000","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nm.3291","article-title":"An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy","volume":"19","author":"Chung","year":"2013","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.celrep.2016.04.028","article-title":"Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy","volume":"15","author":"Pisarsky","year":"2016","journal-title":"Cell Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5114\/wo.2018.73874","article-title":"The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment","volume":"22","author":"Chouaib","year":"2018","journal-title":"Contemp. Oncol. Wsp\u00f3\u0142czesna Onkol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","article-title":"Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: Roles in homeostasis and disease","volume":"31","author":"Locksley","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ge, Z., and Ding, S. (2020). The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.590941"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Jarosz-Biej, M., Kami\u0144ska, N., Matuszczak, S., Cicho\u0144, T., Pamu\u0142a-Pi\u0142at, J., Czapla, J., Smolarczyk, R., Skwarzy\u0144ska, D., Kulik, K., and Szala, S. (2018). M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191012"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Al Tameemi, W., Dale, T.P., Al-Jumaily, R.M.K., and Forsyth, N.R. (2019). Hypoxia-Modified Cancer Cell Metabolism. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00004"},{"key":"ref_127","first-page":"e70700","article-title":"Hypoxia-Inducible Factor 1-Alpha (HIF-1\u03b1) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trecan.2016.11.007","article-title":"Angiogenesis and metabolism: Entwined for therapy resistance","volume":"3","author":"Casanovas","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eaay1371","DOI":"10.1126\/scitranslmed.aay1371","article-title":"Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche","volume":"12","author":"Liu","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Montemagno, C., and Pag\u00e8s, G. (2020). Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00584"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13311-016-0510-y","article-title":"New Directions in Anti-Angiogenic Therapy for Glioblastoma","volume":"14","author":"Wang","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Itatani, Y., Kawada, K., Yamamoto, T., and Sakai, Y. (2018). Resistance to Anti-Angiogenic Therapy in Cancer\u2014Alterations to Anti-VEGF Pathway. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041232"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cytogfr.2009.11.003","article-title":"Pathways mediating VEGF-independent tumor angiogenesis","volume":"21","author":"Ferrara","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","article-title":"A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions","volume":"221","author":"Vimalraj","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"di Tomaso, E., London, N., Fuja, D., Logie, J., Tyrrell, J.A., Kamoun, W., Munn, L.L., and Jain, R.K. (2009). PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005123"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Ribatti, D., Annese, T., and Tamma, R. (2023). Vascular co-option in resistance to anti-angiogenic therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1323350"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2016.01.006","article-title":"Tumor cell vascular mimicry: Novel targeting opportunity in melanoma","volume":"159","author":"Hendrix","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/1078-0432.CCR-11-3237","article-title":"Molecular pathways: Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications","volume":"18","author":"Kirschmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: Perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1038\/onc.2012.578","article-title":"Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis","volume":"32","author":"Semenza","year":"2013","journal-title":"Oncogene"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.2014.55.9575","article-title":"Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma","volume":"33","author":"Duda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","article-title":"Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: An FDA pooled analysis","volume":"25","author":"Goulart","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e00906","DOI":"10.1016\/j.heliyon.2018.e00906","article-title":"Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors","volume":"4","year":"2018","journal-title":"Heliyon"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-15-2529","article-title":"ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI","volume":"22","author":"Gerstner","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/j.semnuclmed.2020.05.001","article-title":"Imaging for response assessment in cancer clinical trials","volume":"50","author":"Sorace","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Gouel, P., Decazes, P., Vera, P., Gardin, I., Thureau, S., and Bohn, P. (2023). Advances in PET and MRI imaging of tumor hypoxia. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1055062"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Alenezi, A., Alhamad, H., Alenezi, A., and Khan, M.U. (2025). Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040459"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Belotti, D., Pinessi, D., and Taraboletti, G. (2021). Alternative vascularization mechanisms in tumor resistance to therapy. Cancers, 13.","DOI":"10.3390\/cancers13081912"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-10-3242","article-title":"Antiangiogenesis enhances intratumoral drug retention","volume":"71","author":"Ma","year":"2011","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"101017","DOI":"10.1016\/j.tranon.2021.101017","article-title":"Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer","volume":"14","author":"Codony","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-12734-3_1","article-title":"Hypoxia mediates tumor malignancy and therapy resistance","volume":"1136","author":"Luo","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/molpharm.122.000525","article-title":"Structural basis for the allosteric inhibition of hypoxia-inducible factor 2 by belzutifan","volume":"102","author":"Ren","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease\u2014Associated Tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Watts, D., Gaete, D., Rodriguez, D., Hoogewijs, D., Rauner, M., Sormendi, S., and Wielockx, B. (2020). Hypoxia pathway proteins are master regulators of erythropoiesis. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202010.0136.v1"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Kucharczyk, J., Bhatt, A., Bauer, L., and Economides, M. (2025). Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157094"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.pharmr.2025.100075","article-title":"Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy","volume":"77","author":"Semenza","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/ijc.23807","article-title":"PX-478, an inhibitor of hypoxia-inducible factor-1\u03b1, enhances radiosensitivity of prostate carcinoma cells","volume":"123","author":"Palayoor","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-023-02724-y","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","article-title":"Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer","volume":"18","author":"Sun","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","article-title":"Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients with Advanced Pancreatic Cancer","volume":"33","author":"Borad","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10637-022-01230-w","article-title":"A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin","volume":"40","author":"McLean","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"109738","DOI":"10.1016\/j.radonc.2023.109738","article-title":"Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability","volume":"186","author":"Yaromina","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic\u2014Immune-checkpoint inhibitor combinations: Lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1158\/1078-0432.CCR-09-1810","article-title":"Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis","volume":"15","author":"Gaur","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Santagata, S., Ieran\u00f2, C., Trotta, A.M., Capiluongo, A., Auletta, F., Guardascione, G., and Scala, S. (2021). CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.591386"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","article-title":"Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy","volume":"15","author":"Ciavattone","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_179","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_180","first-page":"62","article-title":"Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials","volume":"15","author":"Spiegelberg","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1158\/1078-0432.CCR-14-3135","article-title":"Gene Expression Signatures Predictive of Bevacizumab\/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19\/05 trial)","volume":"21","author":"Franzini","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/JHC.S369951","article-title":"Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma","volume":"9","author":"Kaseb","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","article-title":"Vessel co-option and resistance to anti-angiogenic therapy","volume":"23","author":"Kuczynski","year":"2020","journal-title":"Angiogenesis"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Liu, S., Shan, B., Zhang, Y., Xu, L., Zhang, X., Ye, L., Diao, H., Cheng, Y., and Tang, J. (2026). Mechanisms, imaging phenotypes, and therapeutic advances of neovascularization in brain metastases. Biomedicines, 14.","DOI":"10.3390\/biomedicines14010119"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41581-022-00544-5","article-title":"Belzutifan: A novel therapy for von Hippel\u2014Lindau disease","volume":"18","author":"Zhou","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3109\/0284186X.2015.1067721","article-title":"Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia\u2014A simulation study","volume":"54","author":"Wack","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00259-010-1437-x","article-title":"PET imaging of hypoxia using [18F]HX4: A phase I trial","volume":"37","author":"Janssen","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1158\/1078-0432.CCR-15-0018","article-title":"TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"14978","DOI":"10.1038\/s41598-017-14990-w","article-title":"HIF-1\u03b1- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy","volume":"7","author":"Mangraviti","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.medj.2021.10.002","article-title":"LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency","volume":"2","author":"Kallenberg","year":"2021","journal-title":"Med"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"53194","DOI":"10.1021\/acsomega.5c07799","article-title":"Development of a Novel HIF-2\u03b1 PET Tracer for Noninvasive Tumor Hypoxia Imaging","volume":"10","author":"Wang","year":"2025","journal-title":"ACS Omega"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.7150\/thno.84253","article-title":"Photoacoustic imaging for investigating tumor hypoxia: A strategic assessment","volume":"13","author":"Nasri","year":"2023","journal-title":"Theranostics"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Fan, J.H., Fan, G.L., Yuan, P., Deng, F.A., Liu, L.S., Zhou, X., Yu, X.Y., Cheng, H., and Li, S.Y. (2019). A theranostic nanoprobe for hypoxia imaging and photodynamic tumor therapy. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00868"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Brighi, C., Waddington, D.E.J., Keall, P.J., Booth, J., O\u2019Brien, K., Silvester, S., Parkinson, J., Mueller, M., Yim, J., and Bailey, D.L. (2023). The MANGO study: A prospective investigation of oxygen enhanced and blood-oxygen level dependent MRI as imaging biomarkers of hypoxia in glioblastoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1306164"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/bs.mcb.2024.10.016","article-title":"Chapter Fifteen\u2014Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET","volume":"191","author":"Kanli","year":"2025","journal-title":"Methods Cell Biol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00259-018-4116-y","article-title":"Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy","volume":"45","author":"Stieb","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0360-3016(92)91001-4","article-title":"Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole","volume":"22","author":"Koh","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(07)70274-7","article-title":"Non-[18F]FDG PET in clinical oncology","volume":"8","author":"Groves","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Wei, Y., Zhao, W., Huang, Y., Yu, Q., Zhu, S., Wang, S., Zhao, S., Hu, X., Yu, J., and Yuan, S. (2016). A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET\/CT in Patients with Lung Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157606"},{"key":"ref_205","first-page":"253","article-title":"Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy","volume":"46","author":"Eschmann","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.radonc.2020.05.022","article-title":"Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy","volume":"149","author":"Zschaeck","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"20180642","DOI":"10.1259\/bjr.20180642","article-title":"Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI","volume":"92","author":"Robinson","year":"2019","journal-title":"Br. J. Radiol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"W187","DOI":"10.2214\/AJR.12.8969","article-title":"Tumoral hypoxia in osteosarcoma in rats: Preliminary study of blood oxygenation level-dependent functional MRI and 18F-misonidazole PET\/CT with diffusion-weighted MRI correlation","volume":"200","author":"Dallaudiere","year":"2013","journal-title":"Am. J. Roentgenol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/0008-5472.CAN-15-2062","article-title":"Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models","volume":"76","author":"Boult","year":"2016","journal-title":"Cancer Res."},{"key":"ref_210","first-page":"1851","article-title":"Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O","volume":"45","author":"Bruehlmeier","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD","volume":"12","author":"Zang","year":"2022","journal-title":"Theranostics"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.122.265383","article-title":"Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin \u03b1v\u03b23 in Various Cancer Types","volume":"64","author":"Zhao","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jmri.25051","article-title":"Feasibility and reproducibility of BOLD and TOLD measurements in the liver with oxygen and carbogen gas challenge in healthy volunteers and patients with hepatocellular carcinoma","volume":"43","author":"Bane","year":"2016","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/mrm.24543","article-title":"Reproducibility and biological basis of in vivo T2* magnetic resonance imaging of liver metastasis of colorectal cancer","volume":"70","author":"Heijmen","year":"2013","journal-title":"Magn. Reson. Med."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","article-title":"Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically","volume":"7","author":"Chafe","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e177606","DOI":"10.1172\/JCI177606","article-title":"Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models","volume":"134","author":"Verma","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"20418","DOI":"10.1039\/D5RA02235E","article-title":"Therapeutic potential of adenosine receptor modulators in cancer treatment","volume":"15","author":"Maity","year":"2025","journal-title":"RSC Adv."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1295\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:33:47Z","timestamp":1784712827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":217,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141295"],"URL":"https:\/\/doi.org\/10.3390\/cells15141295","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}